THC tells you how strong a product may feel. Terpenes help explain how it may feel. Here’s how Florida medical cannabis patients can use both to shop smarter.

What does the research actually say about cannabis and migraine treatment? This guide breaks down the evidence, THC vs. CBD, terpene questions, product formats, and practical tips for Florida medical cannabis patients.

Cannabis for muscle spasticity is best understood as part of a broader symptom-management plan. Explore clinical applications, cannabis terpenes, storage and stability, and Florida product formats from Green Dragon.

Cannabis can interact with prescription medications in ways patients may not expect. Learn the biggest red flags, safer use habits, and Florida-friendly product formats to discuss with your doctor.

Inflammation gets talked about like it’s always the enemy, but that’s not really how the body works. In the short term, inflammation is protective. It helps you respond to injury, infection, and stress. The problem starts when that response becomes chronic, excessive, or poorly regulated. That’s when inflammation can begin to overlap with pain, stiffness, swelling, immune dysfunction, sleep disruption, and the kind of “always on” discomfort that wears people down over time. The endocannabinoid system, or ECS, is one of the body’s key homeostasis networks, and researchers describe it as a regulator of immune response, pain signaling, and tissue balance. (MDPI)

Pain is personal. It’s also complicated—because “pain” isn’t one thing. Neuropathic pain (nerve pain) behaves differently than arthritis pain. Migraines aren’t the same as back spasms. And the best plan for your symptoms often combines multiple tools: movement, sleep support, stress management, targeted therapies, and—when appropriate—medical cannabis.

In Florida, many patients explore medical cannabis for chronic nonmalignant pain as part of a physician-guided treatment plan. Florida law defines chronic nonmalignant pain as pain caused by (or originating from) a qualifying medical condition that persists beyond the usual course of that condition.

Cannabis topicals are all about targeted support. Think: sore knees after a long walk, tight shoulders after a desk day, overworked hands, post-workout legs, or that “why is my neck doing this?” moment that shows up out of nowhere. Unlike inhalation or oral cannabis, topicals are designed for localized application—you apply them directly to the skin where you want support, rather than sending cannabinoids on a full-body tour.

Let’s break down what topical cannabis products are, what they’re best for, how to dose them, and which options to look for on the Green Dragon FL menu.

Why cannabis can affect anxiety at all

Your body has an internal balancing network called the endocannabinoid system (ECS), involved in mood, stress response, sleep, and more. Cannabinoids like THC and CBD interact with this system (directly or indirectly), which is why cannabis can shift how you experience stress—sometimes toward calm, sometimes the opposite.

The “sometimes the opposite” part matters: the CDC notes cannabis can cause unpleasant thoughts or feelings of anxiety and paranoia for some people.

Dry-ish January isn’t about being perfect—it’s about being intentional. Maybe you’re cutting back on alcohol, skipping it on weeknights, or just trying to wake up in January feeling like yourself instead of a dehydrated raccoon. If you’re a Florida medical marijuana patient, low-dose cannabis can fit that same “less, but better” mindset—especially when you choose formats that make moderation easy.

What a COA is (and why it matters in cannabis Florida)

A COA is a third-party lab report tied to a specific batch (also called lot) of a product. It typically covers two big things:

1. Potency (cannabinoids like THC/CBD, sometimes terpenes)

2. Safety (screens for contaminants like pesticides, heavy metals, microbials, residual solvents, etc.)

In Florida’s medical program, testing labs are certified through the state’s Office of Medical Marijuana Use (OMMU), and OMMU publishes a list of certified marijuana testing laboratories (CMTLs).

The biggest 2025 headline: Rescheduling is back in motion

Late in 2025, President Donald Trump signed an executive order directing the Department of Justice to move more quickly on the ongoing process to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act.

That’s a big deal in cannabis policy terms—but it’s not the same as federal legalization.

Key point: Multiple legal and policy summaries emphasize that a final rule has not been issued, and until it is, marijuana remains Schedule I at the federal level.